SUBSCRIBE: Print / Digital / eNewsletter
A study showing differences in baseline characteristics between responders to anti-tumor necrosis factor (anti-TNF) therapy and insufficient responders may be helpful to dermatologists as they consider treatment for patients with moderate-to-severe psoriasis, according to the investigators. (©SweetheartStudio/Shutterstock.com)
![red psoriasis plaques on elbow](https://www.dermatologytimes.com/sites/default/files/styles/trc_article_348x228/public/Psoriasis_elbow_%D0%9E%D0%BB%D1%8C%D0%B3%D0%B0_%D0%A2%D0%B5%D1%80%D0%BD%D0%B0%D0%B2%D1%81%D0%BA%D0%B0%D1%8F_AdobeStock_221417141_4.jpeg?itok=7F_39czG "<p>“Switching or discontinuing anti-TNFs has significant implications for clinical and economic outcomes in patients with psoriasis; therefore, real-world studies that characterize patients on the basis of response to therapy would provide valuable information to help healthcare providers," write study authors. <small>(Ольга_Тернавская - stock.adobe.com)</small></p>")
A study showing differences in baseline characteristics between responders to anti-tumor necrosis factor (anti-TNF) therapy and insufficient responders may be helpful to dermatologists as they consider treatment for patients with moderate-to-severe psoriasis, according to the investigators.
![red patches of psoriasis on shoulder](https://www.dermatologytimes.com/sites/default/files/styles/trc_article_348x228/public/Shoulder_Psoraisis_Nikkikii_AdobeStock_207606937_6.jpeg?itok=x2fJuh9a "<p>“Before making a switch for primary or secondary failure, clinicians also need to rule out a role for treatment nonadherence," says Ron Vender, M.D. <small>(Nikkikii - stock.adobe.com)</small></p>")
Switching patients with moderate-to-severe plaque psoriasis from one biologic to another is a multifactorial decision and may depend on safety, efficacy or dosing intervals. Ron Vender, M.D., offers insight into how to switch appropriately.
New joint AAD-NPF guidelines consider the quality-of-life impact of pediatric psoriasis as well as comorbidity risks in this patient population.
New topical treatments for psoriasis increasingly prove that vehicles matter, says an expert who spoke at the South Beach Symposium.
Sol-Gel announces updates to their drug pipeline and their goals for 2020, which include submitting multiple provisional patents and NDAs for the treatment of a variety of skin conditions.
![psoriasis on elbow](https://www.dermatologytimes.com/sites/default/files/styles/trc_article_348x228/public/Psoriasis_quayside_AdobeStock_133105410_0.jpeg?itok=S3vPSy47 "<p>"TNF inhibitors are no longer the number-one go-to treatment for psoriasis. But many people are still on them because they started on them before we had the newer agents. It's nice to know that if TNF inhibitors have any risk of cancer associated with them, it must be exceedingly small,” Dr. Fieldman says.</p>")
A Danish study suggests that TNF inhibitors may not increase the risk of developing recurring or new primary cancers in patients with inflammatory diseases.
Ustekinumab’s short-term effect on aortic vascular inflammation points to possible role of IL-12, IL-23 in cardiovascular disease, but more research is needed.
Pediatric patients with psoriasis who experience a significant improvement in disease severity after treatment may experience the greatest positive impact to quality of life, according to a recent study.
Risankizumab (SKYRIZI, AbbVie), outperformed secukinumab (Cosentyx, Novartis) in a head-to-head phase 3 study comparing the two treatments in adult patients with moderate to severe plaque psoriasis, according to data released by the company Jan. 14.
Topical halobetasol propionate 0.01% lotion appears to safely and quickly improve lower-extremity psoriatic lesions, according to a recent study.
We've noticed that you're using an ad blocker
Our content is brought to you free of charge because of the support of our advertisers. To continue enjoying our content, please turn off your ad blocker.
